YOLFTbeta
Jiangsu Jibeier Pharmaceutical Co Ltd

Jiangsu Jibeier Pharmaceutical Co Ltd

688566 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

26.09CNY-0.20 (-0.76%)

Price History

Full chart

Market Stats

Previous Close26.29
Open26.29
Day Range26.05 – 26.90
52-Week Range22.82 – 36.13
Volume1.21M
Market Cap5.52B
P/E (TTM)25.91
Forward P/E0.00
EPS1.06
Dividend Yield1.89%
Beta0.28
50-Day Avg25.67
200-Day Avg27.59

About

Jiangsu Jibeier Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the drug research and development and production in China. The company's products cover multiple therapeutic areas such as increasing white blood cells, fighting hypertension, enhancing immunity, treating joint diseases, fighting eye infections, treating bronchitis, protecting liver function, etc. It is also developing drugs for the treatment of depression, tumors, stomach and gastric diseases, and other diseases. In addition, the company offers its products in tablets, capsules, and eye drops forms. Jiangsu Jibeier Pharmaceutical Co., Ltd. was founded in 2001 and is based in Zhenjiang, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Zhongyi Geng
  • Employees1.38K
  • HeadquartersZhenjiang High-tech Industrial Development Park, Zhenjiang, China, China
  • Websitehttps://www.jbepharm.com

Leadership

  • Mr. Zhongyi GengGM & Chairman of the Board · b. 1963
  • Mr. Xinjun YuVice Chairman of the Board & Deputy GM · b. 1961
  • Mr. Suofu ZhaoFinancial Director · b. 1967
  • Mr. Haidao LiExecutive Vice President of the Research Institute · b. 1983
  • Mr. Jianzhong ZhaiBoard Secretary · b. 1972
  • Mr. Xufeng QinDeputy Director of the Formulation Laboratory · b. 1974
  • Mr. Zhaoguang LiDirector of the Synthesis Office of the Research Institute · b. 1981
  • Ms. Ying WuDeputy General Manager · b. 1952
  • Mr. Xiugen WuResearch Institute Director · b. 1965
  • Zhi Lei ZhuAccounting Supervisor

Financials

Income Statement

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue444.42M452.33M484.96M542.52M565.97M509.69M654.73M860.93M896.53M964.93M
Growth (%)-+1.78%+7.22%+11.87%+4.32%-9.94%+28.46%+31.49%+4.14%+7.63%
Cost of Revenue68.62M67.20M64.17M63.89M64.06M62.12M76.17M97.18M95.26M101.82M
Gross Profit375.81M385.12M420.79M478.63M501.91M447.57M578.56M763.76M801.28M964.93M
Gross Margin84.56%85.14%86.77%88.22%88.68%87.81%88.37%88.71%89.38%100.00%
Operating Expense293.36M292.08M306.57M348.57M351.35M313.94M402.16M514.64M546.62M712.17M
Operating Income82.45M93.04M114.22M130.06M150.56M133.63M176.40M249.11M254.66M252.76M
Operating Margin18.55%20.57%23.55%23.97%26.60%26.22%26.94%28.94%28.41%26.19%
EBITDA104.49M105.33M125.64M142.72M161.94M145.65M187.66M258.93M264.20M308.81M
EBITDA Margin23.51%23.29%25.91%26.31%28.61%28.58%28.66%30.08%29.47%32.00%
Net Income76.94M77.52M96.61M112.91M129.72M114.90M154.67M219.09M219.33M258.67M
Net Income Margin17.31%17.14%19.92%20.81%22.92%22.54%23.62%25.45%24.46%26.81%
R&D16.75M17.14M19.60M31.16M33.55M29.28M55.18M55.77M38.65M40.70M
R&D as % of Total Revenue3.77%3.79%4.04%5.74%5.93%5.75%8.43%6.48%4.31%4.22%
Interest Expense1.83M433.69K100.63K126.45K114.84K105.62K376.23K243.44K239.21K267.02K
Interest Expense % of Total Revenue0.41%0.10%0.02%0.02%0.02%0.02%0.06%0.03%0.03%0.03%

Balance Sheet

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets482.14M527.68M477.99M595.62M1.75B1.82B1.96B2.21B2.53B2.72B
Total Liabilities118.99M86.92M120.32M125.16M170.92M210.40M270.24M299.25M273.68M267.47M
Total Equity356.69M434.22M350.83M463.74M1.57B1.60B1.69B1.90B2.25B2.43B
Cash133.30M201.36M124.91M193.38M1.29B1.03B903.90M694.87M847.48M781.32M
Total Debt19.00M------9.91M20.83M-
Net Debt-114.30M-201.36M-124.91M-193.38M-1.29B-1.03B-903.90M-684.96M-826.65M-

Cash Flow

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow39.29M111.66M97.97M115.45M117.36M150.56M150.72M159.50M215.29M248.30M
Investing Cash Flow-25.88M-19.58M-5.29M-29.55M-5.80M-333.15M-175.49M-364.04M-220.17M-
Financing Cash Flow-13.68M-24.02M-169.14M-17.42M982.42M-89.73M-89.73M-1.23M157.30M-
Capital Expenditure46.69M18.78M8.19M30.22M23.68M83.79M292.70M357.37M174.53M114.60M
Free Cash Flow-7.40M92.88M89.77M85.23M93.68M66.77M-141.98M-197.87M40.76M133.71M
Dividends Paid3.68M5.02M169.14M10.86M44.87M89.73M89.73M44.87M102.95M103.70M
FCF to OCF-18.83%83.18%91.64%73.83%79.82%44.35%-94.20%-124.06%18.93%53.85%
Dividend Paid to FCF-49.70%5.40%188.41%12.74%47.89%134.39%-63.20%-22.67%252.56%77.56%

Earnings

Report DateApr 23, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023
EPS Estimate0.00------------
EPS Actual0.270.110.180.270.140.150.110.210.150.070.200.400.20
Surprise-------------
Timing-------------

Key Statistics & Ratios

Market Cap5.52B
Enterprise Value4.77B
Trailing P/E25.91
Forward P/E0.00
Price / Sales5.52
Price / Book2.24
EPS1.06
Book Value12.51
Revenue (TTM)1.00B
Gross Profit (TTM)896.76M
EBITDA262.98M
Profit Margin21.14%
Operating Margin24.59%
Return on Equity8.52%
Return on Assets5.55%
Shares Outstanding201.10M
Shares Float62.75M
Beta0.28
Dividend Yield1.89%
Dividend Rate0.52
Payout Ratio49.06%

Dividends

20231×
0.24Jun 29, 2023
20222×
0.24Oct 25, 20220.24Jun 17, 2022
20212×
0.24Oct 26, 20210.24Jun 3, 2021
20201×
0.24Oct 19, 2020